Repligen Corp. 10-Q Summary: Period Ended September 30, 2006
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Repligen Corporation, a biopharmaceutical company focused on developing therapeutics for central nervous system diseases and selling commercial products (Protein A and SecreFlo). The report covers the three and six-month periods ended September 30, 2006. The company operates as a single segment with significant revenue concentration in Europe (63% of six-month revenue) and reliance on a few key customers.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Six Months Ended Sep 30, 2006 |
|---|---|---|
| Total Revenue | $2,864,820 | $6,492,988 |
| Net Income (Loss) | $(863,319) | $(762,585) |
| Operating Loss | $(1,096,047) | $(1,217,039) |
| Cash and Cash Equivalents | $5,479,296 | $5,479,296 (Balance Sheet) |
| Total Marketable Securities | $16,554,310 | $16,554,310 (Balance Sheet) |
| Working Capital | $20,485,177 | $20,485,177 |
| Stock-Based Compensation | $255,477 | $504,010 |
Note: Total liquid assets (Cash + Marketable Securities) totaled approximately $22.0 million as of September 30, 2006.
Material Changes vs. Prior Period
- Revenue: Three-month revenue increased 2% to $2.86 million, driven by higher other revenue (research and royalties) offsetting a decline in Protein A product sales. Six-month revenue decreased 8% to $6.49 million, primarily due to lower Protein A sales volume.
- Profitability: The company reported a net loss for both the three and six-month periods in 2006, contrasting with a net loss of $467,508 (three months) and net income of $1.72 million (six months) in the prior year. The prior year's six-month income included a one-time $1.17 million gain from a settlement with ChiRhoClin.
- Expenses: Operating expenses increased 14% ($3.96 million) for the quarter and 13% ($7.71 million) for the six months. Increases were driven by higher clinical trial costs, personnel expenses, and the adoption of SFAS No. 123R, which required the recognition of stock-based compensation expense ($255k for the quarter; $504k for six months).
- Cash Flow: Operating activities used $373,000 in cash for the six months ended September 30, 2006, compared to providing $1.49 million in the prior year. Investing activities provided $409,000, primarily from the redemption of marketable securities.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash and investment balances are adequate to meet needs for at least the next 24 months. Future capital requirements depend on clinical trial success and potential acquisitions.
- Product Outlook: Revenue is currently limited to Protein A and SecreFlo. SecreFlo sales will cease once supplies from the ChiRhoClin settlement are depleted. The company is unable to reliably estimate when therapeutic candidates will generate revenue.
- Legal Proceedings: Repligen and MIT obtained a Summary Judgment in their patent infringement lawsuit against ImClone Systems regarding the production of Erbitux. The court rejected ImClone's patent exhaustion defense. Repligen intends to seek damages for willful infringement.
- Risks: Key risks include dependence on collaborative arrangements, clinical trial results, regulatory approvals, and the ability to raise additional capital. The company has a history of losses and expects to incur continued losses.
Investor Verification Checklist
- Verify the timeline for the depletion of SecreFlo inventory and the resulting impact on future revenue streams.
- Monitor the status of the ImClone patent litigation and potential damage awards.
- Assess the progress and costs of ongoing clinical trials for CNS therapeutic candidates.
- Review the concentration risk associated with the top two customers, who accounted for approximately 68% of product revenue in the quarter.
- Confirm the sufficiency of the $22 million cash position relative to the projected 24-month runway given increased R&D spending.